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ABSTRACT
Stroke is one of the main causes of death and disability worldwide, and the ischemic 
modality is responsible for the majority of these events. Despite its high occurrence 
and potentially unfavorable prognosis, the management options were scarce and 
barely effective until recent times, when a relatively new endovascular intervention 
with demonstrated superior efficacy as compared with that of classic management was 
reported in the medical literature. The theoretical basis of this study was conducted 
through research in virtual databases Public MEDLINE (PubMed) and Scientific 
Electronic Library Online (SciELO) using associations among the keywords “acute 
ischemic stroke”, “ischemic stroke”, “thrombectomy”, “endovascular,” and “intra-arterial 
thrombectomy”. Clinical trials, meta-analysis, and pertinent literature reviews published 
in the last two years were reviewed and 14 articles were selected for complete and 
critical evaluations. The results of the randomized clinical trials, consequences of 
implantation of the intra-arterial thrombectomy as routine management for eligible 
groups, cost-effectiveness, and the most related complications and outcomes associated 
with the procedure are critically explored throughout this study.
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Stroke is one of the main causes of mortality 
and disability worldwide, and the ischemic stroke 
(usually with cardioembolic or arteroembolic 
etiologies) is responsible for the majority of these 
events1. Despite its high occurrence and potentially 
unfavorable prognosis, the management options 
were ineffective in many cases until recent times 
when a relatively new endovascular intervention 
associated with intravenous thrombolysis was reported 
to demonstrate superior efficacy as compared with 
that of the classic intravenous recombinant tissue 
plasminogen activator (IV tPA) management.
Simultaneously with the initial spread of intravenous 
thrombolytics after its approval, endovascular 
intervention techniques in acute strokes from large 
vessel occlusion were developed and tested in several 
medical centers, although data from methodologically 
consistent clinical trials were not yet available2.
A set of clinical trials published mostly in 
2013 indicated a weak significance of the endovascular 
intervention advantages. However, several biases 
were pointed out in these studies, such as the use 
of outdated devices and late medical interventions 
after the onset of the symptoms. Recent pertinent and 
well-designed clinical trials demonstrated different 
results and 2015 became considered as “the year 
of endovascular treatment”3.
In this article, we discuss the results of the randomized 
clinical trials published in the field, the logistic consequences 
of the intra-arterial thrombectomy implantation as a 
routine management tool for eligible groups, cost-
effectiveness, and the most related complications and 
outcomes associated with the procedure.
METHODS
The theoretical basis of this review was carried 
out through searches in virtual databases Public 
MEDLINE (PubMed) and Scientific Electronic Library 
Online (SciELO), using association between the 
keywords “acute ischemic stroke”, “ischemic stroke”, 
“thrombectomy”, “endovascular” and “intra-arterial 
thrombectomy”. Clinical trials, meta-analysis, and 
pertinent systematic literature reviews published in 
English in the last two years were included (figure 1). 
Articles with a non-convenient theme were excluded. 
A total of 13 articles were selected for complete and 
critical parsing. Complementarily, a total of 4 clinical 
trials were included, which, despite not meeting the 
inclusion criteria, were considered fundamental for 
an unbiased discussion of the proposed theme.
Current Concepts
Most acute ischemic strokes are caused by the 
occlusion of large vessels that are mostly components 
of anterior circulation at the proximal middle cerebral 
artery and the intracranial internal carotid artery, but 
also occur in posterior large vessels at the basilar 
artery2. It is important to note that the classic IV 
tPA has relatively low effectiveness in the proximal 
occlusion of large vessels4.
The main purpose of any ischemic stroke treatment 
must be urgent revascularization of the affected area 
to save the parenchyma in the “penumbra area”, an 
event optimized in the endovascular approach by recent 
technologies such as stent retriever apparatuses5.
Intervention with a mechanical device appears to 
have advantages over the isolated use of chemical 
treatments, such as faster revascularization, a 
decreased hemorrhagic rate, and a considerably 
eligible intervention time.
Evidence from Clinical Trials
Although the purpose of this article is to review 
the main evidence published over the last two years, 
older clinical trials such as IMS III, SYNTHESIS, 
MR RESCUE and THERAPY are crucial for a full 
and unbiased overview of the subject.
In the IMS III6 and SYNTHESIS7 trials it was 
found that the endovascular therapy and intravenous 
t-PA groups were similar for mortality at 90 days and 
symptomatic intracerebral hemorrhage within 30 hours 
after initiation of t-PA. These studies indicated that 
endovascular therapy is not superior to standard 
treatment with intravenous t-PA. The MR RESCUE8 
trial demonstrated that mean scores on the modified 
Rankin scale did not differ between groups even when 
subdivided according to the presence of penumbral 
or a nonpenumbral pattern on computed tomography 
or magnetic resonance imaging of the brain.
Thus, there were those who believed that 
these studies had determined the non-superiority 
of the endovascular therapy when compared to 
intravenous t-PA. However, limitations pointed out 
in these studies and posteriorly published trials 
have refuted such conclusion. Assessments have 
criticized the common delay between symptom 
onset and treatment, suboptimal optimal rates of 
recanalization, prevailing use of outdated devices, 
inconsistent use of appropriate imaging as a inclusion 
criteria, and statistical inadequacies3,9. Five clinical 
trials published in 2015 demonstrated the viability of 
the endovascular approach in acute ischemic stroke.
In the study EXTEND-IA10, researchers analyzed 
earlier intervention (4.5 h after the onset of the 
symptoms). Patients diagnosed with acute ischemic 
stroke, specified as penumbra area and ischemic 
parenchyma with a volume less than 70 ml, were 
evaluated with a computer tomography (CT) due to 
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occlusion of the internal carotid or middle cerebral 
artery. These patients received alteplase (0.9 mg/kg), 
and were either submitted to the intra-arterial 
thrombectomy group using a Solitaire FR stent 
retriever or a conservative group receiving only 
tPA. Patients in the treatment group experienced a 
greater area of vascularized penumbra tissue, earlier 
clinical neurologic improvement 3 days after the 
procedure, and better functional outcome at 90 days 
as compared with those in the conservative group. 
No differences were noted in the rates of death or 
symptomatic hemorrhage between the two groups.
The SCAPE11 trial investigators also evaluated 
the benefits of endovascular treatment in association 
with intravenous thrombolysis. Subjects with a 
proximal intracranial arterial occlusion without a 
large ischemic area and an Alberta Stroke Program 
Early Computed Tomography Score (ASPECTS) 
between 6 and 10 were evaluated. The mean time 
from CT to reperfusion was 84 min. Better rates of 
functional independence and reduced mortality were 
observed when comparing the intervention with the 
control group.
In order to assess patients with proximal anterior 
intracranial occlusion without a large ischemic 
area, the SWIFT PRIME12 trial was performed. 
After the initial clinical presentation of the stroke, 
patients received intravenous tPA for 4 h and 30 min 
and thrombectomy using a stent retriever for 6 h. 
The results indicated reduced disability at 90 days, 
higher functional independence in the intervention 
group, and no substantial differences related to 
mortality and intracranial symptomatic hemorrhage 
between the two groups.
The REVASCAT13 trial investigators found that 
patients with confirmed proximal anterior intracranial 
circulation without a large ischemic area defined as 
ASPECTS of 7 to 10, who were treated up to 4-5 h 
after the ictus with intravenous alteplase associated 
with thrombectomy using solitaire stent retriever up to 
8 h after the ictus, demonstrated a reduced severity in 
disability and improved functional independence, with 
no differences of intracranial symptomatic hemorrhage 
when compared to alteplase therapy alone.
Lastly, MR CLEAN14 researchers applied, up to 
6 h after the onset of symptoms, the intra-arterial 
thrombectomy associated (in eligible patients) with 
intravenous (between 4-5 h) and intra-arterial tPA in 
patients with confirmed proximal anterior arterial 
cerebral circulation occlusion. Improved rates of 
functional independence in the intervention group 
and no differences in the mortality or symptomatic 
intracerebral hemorrhage were reported between 
the intervention and no-intervention groups.
Additionally, In the THERAPY15 trial it was 
found that it is possible that an alternate method 
of thrombectomy, without stents retrievers, can be 
effective for specific patients harboring large vessel 
occlusions. In the meantime, the authors argue that 
Figure 1: Article selection methodology.
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the results are not imperative, demanding further 
research.
DISCUSSION
Trials using more specific inclusion criteria had 
better clinical outcomes and prognosis than trials 
where patients were admitted with larger areas of 
penumbra and late presentations. It can also be 
noted that studies with simplified inclusion criteria 
showed unreliable results. CT angiography was 
performed in the ESCAPE Trial, resulting in a careful 
selection of patients, which had better outcomes with 
the procedure than those using only a conventional 
CT, such as MR CLEAN patients. These findings 
highlight the importance of criterion selection for 
intra-arterial thrombectomy. However, a simple and 
cheaper method is a more realistic possibility in the 
context of Brazilian public health, demanding an 
accurate search for possible radiological findings 
that indicate eligibility for the intervention.
It is evident that these five clinical trials demonstrated 
comparable methodology and compatible results. 
The reproducibility of the results indicates a high rate 
of confidence regarding the variable analyzed: the 
intra-arterial thrombectomy with stent retriever clinical 
outcomes after a proximal artery occlusion compared 
with the use of IV rTPa alone. It is noteworthy to 
mention that in three of the five studies, the research 
was stopped prematurely because of the discrepancy 
of efficacy between the approaches (table 1).
Cost-effectiveness, Complications, and Anes-
thesia Related to the Procedure
To assess the cost-effectiveness of intra-arterial 
thrombectomy implantation as the standard 
management of the ischemic event, Aronsson et al.16 
used a mathematical model (Markov model) to 
generalize the data arising from the five clinical 
trials discussed above from 90 days to a lifelong 
time period. The outcomes such as quality of life 
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and disability are closely related to the costs and 
benefits at a population level. Important financial 
benefits were estimated, such as savings around 
$221 per patient, including a big range of factors, 
such as rehabilitation, medicaments, follow-up, and 
home-care costs.
Since it is a very recent procedure, long-term 
studies that analyze long-dated clinical and economic 
factors of the intra-arterial thrombectomy in the 
management of acute ischemic stroke are not yet 
available. There are still substantial obstacles such 
as logistics, sedation, imaging exams, manpower, 
and financial aspects that need to be overcome 
to promote the implementation of endovascular 
management as a standard care.
Regarding the occurrence of atypical events and 
complications related to the procedure, the leading 
event was puncture site complications, followed 
by hemorrhagic events (hemorrhagic infarction or 
parenchymal hematoma), procedure-/device-related 
events (such as stent detachment, arterial dissection 
and vascular perforation) and late-onset occurrences 
(vascular stenosis, usually asymptomatic)17.
Hemodynamic variables are clearly related to more 
severe outcomes, especially with huge variability 
in blood pressure and hypotension. A retrospective 
review18 proposed that conscious sedation was 
associated with more favorable outcomes and related 
to a lower variability in systolic blood pressure when 
compared to general anesthesia. Therefore, it has 
been suggested that the anesthetic technique may 
play an important role in the clinical outcome.
CONCLUSIONS
The new findings in the literature clearly 
demonstrate that intra-arterial thrombectomy promotes 
important clinical and economic benefits pertinent 
to acute ischemic stroke management. However, it 
is indispensable to establish new functional logistic 
routines concerning acute stroke management in 
order to properly implement the new techniques. In 
the future, standardization of eligible criteria for the 
procedure needs to be determined.
There are many variables to be elucidated, in part 
due to the relatively low number of patients, which will 
impair subject division into subgroups for significant 
statistical analysis. The practical challenges for the 
dissemination of the approach remain to be studied, 
such as logistical aspects of imaging, sedation, and 
cost. However, endovascular therapy appears as a 
potential intervention technique for acute ischemic 
stroke with emphasis in large vessels occlusion.
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